DARPA Antibody Technology Program, Phase II: Characterization of an Anti-BclA Antibody Produced by U.S. Naval Research Laboratory
Abstract
The Defense Advanced Research Projects Agency (DARPA; Arlington, VA) Antibody Technology Program focused on development of technologies that enhance the thermal stability and binding affinity of a given antibody. In this study, the U.S. Army Edgewood Chemical Biological Center (ECBC; now known as U.S. Army Combat Capabilities Development Command Chemical Biological Center; Aberdeen Proving Ground, MD) functioned as an independent testing laboratory to provide technical support on immune reagents and assist in defining the government-supplied antibody-antigen pairs. Project goals were to (1) implement standardized methods for characterizing antibodies developed at ECBC with de novo thermal and binding properties of select reagents for use by DARPA-funded investigators, and (2) use those methods to validate changes in antibody thermal stability and binding affinities achieved by DARPA investigators. The BA21 antibody, which detects BclA of Bacillus anthracis, was chosen for this project. This report describes evaluation of BA21 antibodies (supplied by U.S. Naval Research Laboratory; Washington, DC) for affinity and stability enhancements. Results of this study provide standardized parametric data on antibody properties and performance and contribute to the development of decisional analysis tools for selecting antibody-based reagents that optimize field-operation and performance metrics for future detection and diagnostic platforms.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2019
- Accession Number
- AD1074346
Entities
People
- Alena M. Calm
- Candice Warner
- Darrel Menking
- Heather Welsh
- James Carney
- Melody Zacharko
- Patricia E. Buckley
- Roy Thompson